Searchable abstracts of presentations at key conferences in endocrinology

ea0039ep41 | Diabetes | BSPED2015

Variation in 24-h basal insulin requirements with age in children and young people with type 1 diabetes mellitus

Peters Catherine , Hindmarsh Peter

Introduction: Insulin requirements change with age, in part related to changes in Growth Hormone secretion. Little is known of the impact of age on the circadian variation in insulin secretion. We have studied changes in insulin basal rates as a proxy for insulin sensitivity in CYP with well controlled T1DM.Methods: Insulin pump settings for total daily dose (TDD) and sensitivity ratio were obtained from 22 CYP with T1DM. Basal insulin requirements were ...

ea0058oc5.4 | Oral Communications 5 | BSPED2018

Fourteen years’ experience of hydrocortisone pump therapy for cortisol replacement in adrenal insufficiency

Hindmarsh Peter , Honour John

Conventional hydrocortisone dosing does not mimic the normal cortisol circadian rhythm making treatment optimisation difficult in patients with adrenal insufficiency. We described the first use of a continuous variable subcutaneous hydrocortisone infusion (CSHI) via an insulin pump to replace cortisol in a patient with congenital adrenal hyperplasia (CAH) to mimic the normal plasma cortisol circadian rhythm. We report the long term experience of CSHI in seven patients with adr...

ea0058p006 | Adrenal | BSPED2018

Questionnaire survey identifies timing of last dose of hydrocortisone as important determinant of side effects

Hindmarsh Peter , Honour John

The aim of cortisol replacement in adrenal insufficiency is to mimic the normal cortisol circadian rhythm. Timing of the last dose varies. Paediatric practice doses as close to midnight or after as possible compared to no dose after 18.00 h in adults. Using a detailed questionnaire, we ascertained side effect prevalence in 226 patients with adrenal insufficiency (77 CAH, 82 Addison, 67 hypopituitarism) and compared frequency of problems with timing glucocorticoid replacement. ...

ea0033p46 | (1) | BSPED2013

‘Bridging The Gap’: improving glycaemic control for children of African descent in London

Pichierri Jennifer , Hindmarsh Peter

Children and adolescents with type 1 diabetes treated at University College Hospital London (UCLH) from an African background have poorer glycaemic control compared to the British population (British mean HbA1c 7.8 (0.1), African mean HbA1c 9.4 (0.5) P<0.001).Haemoglobin A1c is an element of the haemoglobin to which glucose is bound. The ideal range is between 6.5 and 7.5% and is considered to represent good glycaemic control. Patients who p...

ea0039ep126 | Thyroid | BSPED2015

Neonatal thyrotoxicosis – a single centre case series

Langham Shirley , Hindmarsh Peter , Peters Catherine

Introduction: Neonatal thyrotoxicosis is rare and occurs with transfer of Thyrotropin Receptor Antibodies (TRAb) across the placenta in a mother with a history of Grave’s disease. The neonatal mortality rate can be as high as 20%, usually secondary to cardiac failure. Therefore prompt diagnosis and treatment is essential.Methods: We report a series of seven infants with neonatal thyrotoxicosis seen in the Endocrine clinic between 2011 and 2015. Mate...

ea0058p003 | Adrenal | BSPED2018

Differences in hydrocortisone absorption during the 24 hour period in patients with adrenal insufficiency

Hindmarsh Peter , Charmandari Lia , Honour John

Hydrocortisone therapy should be individualised in patients with adrenal insufficiency to avoid over and under replacement. We assessed hydrocortisone absorbtion at different times of day which may impact on treatment regimens. We assessed the oral absorption of hydrocortisone in 48 patients (21M) aged between 6.1 and 20.3 years with congenital adrenal hyperplasia due to P450c21 deficiency. Hydrocortisone dosing ranged between 11.5 and 22.6 mg/m2 per day in three or...

ea0033p25 | (1) | BSPED2013

Gene expression profiling reveals possible role of growth factors in beta cell hyperplasia in congenital hyperinsulinism

Senniappan Senthil , Hindmarsh Peter , Hussain Khalid

Introduction: Congenital hyperinsulinism (CHI) is a clinically heterogeneous condition. Mutations in ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, HNF4A, UCP2 and HNF1A are known to cause CHI. There are two histological subtypes of CHI: diffuse and focal. Apart from the functional channel defect, β-cell hyperplasia has been observed in diffuse CHI. We aimed to understand the gene expression pattern in pancreatic tissue of patients with diffuse CHI when compared to normal cont...

ea0036oc7.2 | Oral Communications 7 | BSPED2014

Urinary vitamin E metabolites as a biomarker of oxidative stress in type 1 diabetes

Bulwer Chloe , Mills Kevin , Sirka Ernestas , Hindmarsh Peter

Background: Oxidative stress has been implicated in the development and progression of complications in type 1 diabetes (T1DM). Vitamin E (α-tocopherol) undergoes β-oxidation of its chomanol ring and the resulting metabolite α-TLHQ has been proposed as a potential biomarker of oxidative stress. HbA1c relates in T1DM to microvascular complications predominantly although the end-points are late in disease development. The oxidative stress process may act independe...

ea0027oc4.3 | Oral Communications 4 | BSPED2011

Non-linear dynamic analysis of glucose regulation in subjects with type 2 diabetes and controls: observed variability and lability (OVAL)

Hill Nathan , Hindmarsh Peter , Tsapas Apostolos , Matthews David

Introduction: Glucose homeostasis is central to the understanding of diabetes and is influenced by hormones and by substrate flux. This implies a non-linear system which has been confirmed by time series analysis. A dynamic systems approach is required for describing the inter-relationship of glucose and insulin and we describe a method that measures a mathematical domain of glucose homeostasis termed the observed variability and lability (OVAL).Methods:...

ea0027oc5.1 | Oral Communications (RCN CYP Diabetes Session) | BSPED2011

Continuous subcutaneous insulin infusion (CSII) at diagnosis

Potts Louise , Thompson Rebecca , Hindmarsh Peter , Agostini Kirsty

The incidence of type 1 diabetes in children under 5 years is increasing. The insulin requirements, eating regimens and reaction to invasive procedures make this group a challenging cohort to manage on multiple daily injections. NICE Guidance was amended in 2008 to include the option of using CSII at diagnosis in the under 5’s.Seven CSII starts at diagnosis have been done (from 2009 to current). CSII is initiated within 72 h from initial diagnosis, ...